Clinical Trial

Effect of a Dietary Supplement on Gut Microbiota and Ocular Surface Outcomes in Dry Eye Disease

Completed
View on ClinicalTrials.gov →
Summary
This prospective clinical study investigates whether a dietary supplement product can modulate the gut microbiota and improve ocular surface outcomes in patients with dry eye disease. Participants will be recruited from Istanbul Medipol University Hospital (Department of Ophthalmology) and Liv Hospitals (Vadi Istanbul and Ulus). Each participant will receive the dietary supplement product for 8 weeks. Gut microbiota analyses will be conducted at baseline and week 8. Ocular surface assessments including Schirmer test and invasive tear breakup time (TBUT) will be performed at baseline and week 8.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-08-22; most recent amendment 2026-02-16.
Status change: Recruiting → Completed 2026-01-14
Trial Details
NCT Number NCT07148271
Lead Sponsor Varol TUNALI
Collaborators: Istanbul Medipol University Hospital, Liv Hospital (Ulus)
Conditions Dry Eye, Meibomian Gland Dysfunction (Disorder), Dry Eye Disease (DED), Dry Eye Disease, Meibomian Gland Disease
Enrollment 20 participants
Start Date 2025-10-01
Primary Completion 2025-12-20 (estimated)
Study Completion 2026-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-02-18